Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW...
Source: prnewswire.com